Endocrine Society to host virtual Science Writers Conference Nov. 14 Surging demand for a new generation of highly effective anti-obesity medications is creating interest in compounded versions of these medications. Endocrine Society experts will discuss the importance of prescribing FDA-approved medications to treat obesity during the Society’s Virtual Science Writers Conference on November 14. What:...
Q&A with Rohit N. Kulkarni, MD, PhD On the heels of receiving nearly $10 million from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Rohit N. Kulkarni, MD, PhD, discusses how his team will use this grant to pursue new approaches to studying type 2 diabetes and obesity by exploring gene expression...
Innovations on the forefront of glucose monitoring and insulin delivery are revolutionizing the state of diabetes care. Staying abreast of the latest advancements in diabetes technology is critical for improving patient care. The field of diabetes management continues to rapidly evolve with products designed to optimize glucose monitoring, insulin delivery, and patient convenience. Next-generation continuous...
Daniel Drucker, MD, recent winner of our Lifetime Achievement Laureate Award, the top honors in the field, shares his story as one of the pioneers in advancing next-generation anti-obesity medications such as Ozempic in a new video series on obesity care. Drucker, who is a senior investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health, and a...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * First Successful Clinical Trial with Anti-CD40L Antibody is Completed On October 29, a potentially major advancement for type 1 diabetes treatment was announced by the University of Miami Diabetes Research Institute (UM-DRI), in collaboration with the University of Chicago, regarding the...
A Town Hall sponsored by the Endocrine Society’s Early-Career Special Interest Group (SIG) provided attendees with insight into the professional journeys of a basic scientist, a translational scientist, and a physician-scientist. The Early-Career Special Interest Group (SIG) Webinar “Insider Insights in the Scientist Pathway” welcomed three highly accomplished professors last week, who each shared valuable...
Endocrine Society members David J. Mangelsdorf, PhD; Erica Elizabeth Marsh, MD, MSCI; and Margaret M. McCarthy, PhD have been elected to the National Academy of Medicine (NAM). David J. Mangelsdorf, PhD, is professor and chair, department of pharmacology, and investigator, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas. He was noted for...
This month’s focus is in an area that has actually been in the mainstream media quite a bit in the last few years: reproduction. However, of course we are putting our own endocrine-focused spin on it with several stories about the impact endocrine science has made on human reproduction. For our cover story, “Texas Nexus:...